IDH1 and astrocytoma (excluding glioblastoma): reported results from the NOA16 Phase I trial, a multicenter, open‐label study evaluating an IDH1‐vac peptide vaccine in 33 newly diagnosed Grade 3/4 IDH1 (R132H) astrocytoma patients.